Meeting
2022 ASCO Annual Meeting
Comprehensive genomic and immune profiling defines immunotherapy treatment in patients with NSCLC with low PD-L1 IHC.
Authors
Sarabjot Pabla
OmniSeq, Inc., Buffalo, NY
Sarabjot Pabla , Robert J. Seager , Mary Nesline , Paul DePietro , Erik Van Roey , Shuang Gao , Shakti Ramkissoon , Lei Deng , Shengle Zhang , Roger David Klein , Jeffrey M. Conroy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2623)
DOI
10.1200/JCO.2022.40.16_suppl.2623
Abstract #
2623
Poster Bd #
278
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Stereotactic body radiation therapy and in situ oncolytic virus therapy followed by immunotherapy in metastatic non-small cell lung cancer.
First Author: Carlo Guerrero
Poster
2024 ASCO Annual Meeting
Phase 1 study of CTX-471, a novel CD137 agonist antibody, in patients with progressive disease following PD-1/PD-L1 inhibitors in metastatic or locally advanced malignancies.
First Author: Minal A. Barve
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Benefit of immune checkpoint inhibitors (ICI) for patients with advanced esophageal squamous cell carcinoma and low PD-L1 expression: A systematic review and meta-analysis.
First Author: Mario Machado Lopes
Poster
2023 ASCO Annual Meeting
A comprehensive pan-cancer analysis of PD-L1 expression using clone E1L3N in Chinese patients with cancer.
First Author: Huangbin Lu